Syngene Strengthens Biologics Offering with Integrated mAb and Bioconjugation Capabilities

Syngene International Ltd has confirmed the expansion of its biologics facility with the addition of antibody-drug conjugate (ADC) bioconjugation capabilities, aimed at enhancing integrated services across the biologics value chain. 

The new suite of capabilities will allow the company to carry out both monoclonal antibody (mAb) production and GMP bioconjugation at a single site, thereby streamlining development timelines and supporting end-to-end ADC services.

Integrated Capabilities for ADC Development

The expanded facility will offer fully integrated services for ADCs, covering stages from discovery through GMP manufacturing. This addition complements existing commercial capabilities in payload and linker manufacturing, allowing for more cohesive operations within the biologics space. 

The investment in bioconjugation forms part of the company’s ordinary business activities and aims to support ongoing efforts in biologics development while enhancing the company’s integrated service offerings.

The facility is expected to accelerate development timelines significantly, providing clients with the convenience of managing mAb production and bioconjugation at a single location, reducing the need for multiple handovers and improving operational efficiency.

Quarterly Financial Performance

For the quarter, Syngene International reported a revenue increase of 10.7% year-on-year to ₹874.5 crore, surpassing estimates of ₹853.1 crore. EBITDA rose to ₹206.4 crore from ₹169.8 crore in the previous year, exceeding the estimated ₹191.9 crore.

The EBITDA margin improved by 210 basis points to 23.6% from the year-ago quarter, higher than the estimated 22.5%. However, compared with the previous quarter, revenue and EBITDA were lower by 14.1% and 40% respectively, while the EBITDA margin narrowed from 33.8% recorded in the March quarter.

Market Position and Share Performance

As of 1:47 PM on October 24, 2025, the Syngene International share price was trading at ₹657, down 0.79% on the BSE. The company, listed under BSE: 539268 and NSE: SYNGENE, has a market capitalisation of ₹26,475 crore.

Established in 1993 as a Biocon subsidiary, Syngene International is India’s first Contract Research Organisation (CRO). Over the years, it has evolved into an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). 

Read More: Syngene Shares Hit 10% Lower Circuit After Reporting 3% YoY Drop in Q4 Net Profit to ₹183 Crore

Conclusion

The expansion with ADC bioconjugation capabilities reinforces Syngene’s focus on offering comprehensive biologics solutions, allowing the company to meet client needs efficiently and support accelerated development timelines across complex biologics projects.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.